Yahoo
HKSE - Delayed Quote HKD

China Shineway Pharmaceutical Group Limited (2877.HK)

7.510 +0.090 (+1.21%)
As of 1:26:17 PM GMT+8. Market Open.
Chart Range Bar
Loading chart for 2877.HK
  • Previous Close 7.420
  • Open 7.400
  • Bid 7.505 x --
  • Ask 7.510 x --
  • Day's Range 7.390 - 7.520
  • 52 Week Range 7.120 - 10.470
  • Volume 290,000
  • Avg. Volume 1,471,763
  • Market Cap (intraday) 5.673B
  • Beta (5Y Monthly) 0.68
  • PE Ratio (TTM) 6.36
  • EPS (TTM) 1.180
  • Earnings Date (est.) --
  • Forward Dividend & Yield 1.42 (19.14%)
  • Ex-Dividend Date Oct 2, 2026
  • 1y Target Est 8.57

China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People's Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; and other dosage forms, including pills and tablets; and traditional Chinese medicine granules in various therapeutic areas, including respiratory system disease, nervous system, digestive system disease, cardiovascular and cerebrovascular, orthopedics, pediatrics, chronic illnesses, and other areas, as well as medication for strengthening the body. It is also involved in the trading of agricultural products. The company was incorporated in 2002 and is headquartered in Shijiazhuang, China. China Shineway Pharmaceutical Group Limited operates as a subsidiary of Forway Investment Limited.

www.shineway.com.hk/en/index.aspx

2,656

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/3/2026, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

2877.HK
17.46%
HANG SENG INDEX (^HSI)
8.37%

1-Year Return

2877.HK
17.73%
HANG SENG INDEX (^HSI)
10.22%

3-Year Return

2877.HK
63.69%
HANG SENG INDEX (^HSI)
32.96%

5-Year Return

2877.HK
71.60%
HANG SENG INDEX (^HSI)
6.15%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY24
Revenue 891.04M
Earnings --
Profit Margin 0.00%

Q2

FY11

Q3

FY11

Q4

FY11

Q4

FY24

0
200M
400M
600M
800M
0.0%

Analyst Insights

View More

Analyst Price Targets

8.57
8.57 Average
7.510 Current
8.57 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    30.20%

  • Return on Assets (ttm)

    3.90%

  • Return on Equity (ttm)

    10.05%

  • Revenue (ttm)

    2.66B

  • Net Income Avi to Common (ttm)

    804.44M

  • Diluted EPS (ttm)

    1.180

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.54B

  • Total Debt/Equity (mrq)

    3.81%

  • Levered Free Cash Flow (ttm)

    476.11M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: